A61K 2039/605
Mhc molecules or ligands thereof
Official title: {MHC molecules or ligands thereof}
A61K2039/605 (Mhc molecules or ligands thereof) appears on 218 US grants and 457 published applications in this corpus.
Search patents in A61K- Granted patents
- 218
- Published applications
- 457
- Assignees
- 179
- Inventors
- 597
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 2 | 0 |
| 2002 | 4 | 9 |
| 2003 | 2 | 11 |
| 2004 | 12 | 19 |
| 2005 | 12 | 26 |
| 2006 | 3 | 11 |
| 2007 | 0 | 5 |
| 2008 | 0 | 11 |
| 2009 | 5 | 16 |
| 2010 | 1 | 9 |
| 2011 | 8 | 14 |
| 2012 | 3 | 16 |
| 2013 | 4 | 9 |
| 2014 | 8 | 8 |
| 2015 | 6 | 15 |
| 2016 | 7 | 24 |
| 2017 | 4 | 10 |
| 2018 | 15 | 22 |
| 2019 | 10 | 22 |
| 2020 | 14 | 35 |
| 2021 | 17 | 28 |
| 2022 | 16 | 33 |
| 2023 | 8 | 31 |
| 2024 | 13 | 28 |
| 2025 | 19 | 27 |
| 2026 | 8 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Production of MHC II/CII complexes1 Sep 2026US 12,721,884 B2
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Individualized vaccines for cancer2 Jun 2026US 12,642,844 B2BioNTech SE
- Peptide deficient-MHC class I/chaperone compositions and methods19 May 2026US 12,630,606 B2The Regents of the University of California
- HLA-DR/CII peptide complexes for treating arthritis12 May 2026US 12,622,946 B2
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
- Methods for Treating HPV16-Associated Cancers20 Aug 2026US 2026/0240979 A1Cue Biopharma, Inc.
- Tau and amyloid beta peptide immunogen compositions and related methods6 Aug 2026US 2026/0224676 A1Vaxxinity, Inc.
- Tau peptide immunogen constructs30 Jul 2026US 2026/0216305 A1Vaxxinity, Inc.
- Nucleic acid molecules23 Jul 2026US 2026/0209739 A1CureVac AG
Most cited
By later US patents
- Prevention and treatment of amyloidogenic disease160US 6,743,427 B1Neuralab Limited · 2004
- Humanized and chimeric N-terminal amyloid beta-antibodies109US 6,750,324 B1Neuralab Limited · 2004
- Passive immunization of Alzheimer's disease99US 6,913,745 B1Neuralab Limited · 2005
- Methods of treatment of Alzheimer's disease96US 6,875,434 B1Neuralab Limited · 2005
- Prevention and treatment of amyloidogenic disease96US 6,972,127 B2Neuralab Limited · 2005